ENSG · Ensign Group, Inc
$181.65
-0.23 (-0.13%)
At close · Aug 14
Market Cap
$10.59B
Shares
58.28M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$181.65
Open$182.14
Day$180.94–182.55
52W close$147.13–215.83
Avg vol 30d438K
Short int1.7M · 2.9% float · 3.2d
Short vol58%
Last earningsJul 29, 2026
DataJan 2020–Aug 2026
Filing10-Q · Jul 27
Up next
Next earnings call
Oct 28, 2026
Est · unconfirmed
· in 10 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Jul 27, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Neutral
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Moderate
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−1%
below
Price vs 50-day avg
+8%
above
RSI (14)
60
neutral
MACD trend
Negative
52-week position
50%
mid-range
Momentum
relative strength
1-month return
+6%
trailing
6-month return
−15%
trailing
YTD return
+4%
this year
Relative strength
−29%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $168 › 200d $183 — 200d above 50d
Institutional flow
Distributing
-7% holders QoQ · +83 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.89% of float · ▼ -22.3% MoM · 3.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
537 holders — mid 3-yr range
Squeeze score
58
elevated · 0–100
Fundamentals
Revenue growth
+19%
Y/Y
EPS growth
+14%
Y/Y
Free cash flow
$492.7M
Valuation
P/E 28.5
rich
Buyback
$60.0M
remaining
Balance sheet
$362.1M
net cash
Quant / Vol
risk profile
Volatility
28%
annualized · 1-yr
Max drawdown
−32%
past year
ATR
2.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Jul 27, 2026
Earnings per diluted share
· annual 2026
$7.75 – $7.85
Revenue
· annual 2026
$5.87B – $5.92B
Prior guidance
period ended
· from the 8-K filed Nov 3, 2025
Earnings guidance
· annual 2025
$6.48 – $6.54
Revenue guidance
· annual 2025
$5.05B – $5.07B
Guided vs delivered
· last 4 settled
Earnings guidance
annual 2025
guided $6.48 – $6.54
$5.84
Miss −10.3%
Revenue guidance
annual 2025
guided $5.05B – $5.07B
$5.06B
In line
Annual 2024 earnings guidance
annual 2024
guided $5.29 – $5.47
$5.12
Miss −4.8%
Annual revenue guidance
annual 2024
guided $4.13B – $4.17B
$4.26B
Beat +2.7%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−1%
Neutral
Price vs 50-day avg
+8%
Bullish
RSI (14)
60
Neutral
MACD trend
Negative
Bearish
52-week position
50%
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $168 › 200d $183 — 200d above 50d
Institutional flow
Distributing
-7% holders QoQ · +83 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.89% of float · ▼ -22.3% MoM · 3.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
537 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $147
Now $182 · 50%
Range high $216
vs 200-day avg -1%
vs 50-day avg +8%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted Earnings Per Share non-GAAP | $1.92 | Three Months Ended June 30, 2026 | — |
| Adjusted Net Income non-GAAP | 114.31M | Three Months Ended June 30, 2026 | — |
|
|
|||
GAAP → non-GAAP reconciliationGAAP Net income attributable to The Ensign Group, Inc. 99.74M
+16.17M Stock-based compensation expense(1)
+0K Cost of services - loss (gain) on long-lived assets and business interruption recoveries
+519K Cost of services - acquisition related costs(2)
+2.18M General and administrative - costs incurred related to system implementations
+0K Depreciation and amortization - patient base(3)
-4.3M Provision for income taxes on Non-GAAP adjustments(4)
= Adjusted Net Income 114.31M
|
|||
| Number of affiliated facilities | 398 | Q2 2026 | — |
| Same Facility occupancy | 84.1% | Q2 2026 | — |
| Transitioning Facility occupancy | 84.7% | Q2 2026 | — |
| Same Facilities occupancy | 84.3% | first quarter of 2026 | — |
|
|
|||
| Same Facilities skilled days | 4.4% | first quarter of 2026 | — |
| Transitioning Facilities occupancy | 85.1% | first quarter of 2026 | — |
|
|
|||
| Transitioning Facilities skilled days | 9.3% | first quarter of 2026 | — |
| Adjusted Diluted Earnings Per Share non-GAAP | $6.57 | year ended December 31, 2025 | — |
| FFO non-GAAP | $75.2M | year ended December 31, 2025 | — |
GAAP → non-GAAP reconciliationGAAP Segment income 37.62M
+37.6M Depreciation and amortization
= FFO 75.22M
|
|||
| Number of facilities at period end | 210 | quarter ended December 31, 2025 | — |
| Recently Acquired Facility actual patient days | 498,793 | quarter ended December 31, 2025 | — |
| Recently Acquired Facility number of facilities at period end | 68 | quarter ended December 31, 2025 | — |
| Same Facility actual patient days | 1,938,015 | quarter ended December 31, 2025 | — |
| Transitioning Facility actual patient days | 432,877 | quarter ended December 31, 2025 | — |
| Transitioning Facility number of facilities at period end | 48 | quarter ended December 31, 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ENSG
this stock
Ensign Group, Inc
|
$10.59B | +4.3% | +18.7% | 28.5 | 2.9% |
|
HCA
HCA Healthcare, Inc.
|
$89.77B | -13.3% | +7.1% | 13.9 | 2.7% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$30.87B | -4.4% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$21.57B | +34.8% | +0.9% | 10.3 | 4.0% |
|
FMS
Fresenius Medical Care AG
|
$12.65B | -0.2% | +5.9% | — | 0.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ENSG | -0.7% | +6.1% | -15.2% | +2.0% | +4.3% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -1.1% | +1.6% | -29.0% | -2.0% | -9.6% |
Capital returns
Latest dividend
$0.065
/ share · ex Jun 30, 2026
Paid (TTM)
$0.258
/ share · 4 payouts
Dividend yield (TTM, derived)
0.14%
Buyback program
· as of Jun 30, 2026
Authorized
$100.00M
Spent (derived)
$40.00M
Remaining
$60.00M
Spent
Remaining
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
Key facts
CIK
1125376
CUSIP
29358P101
13F (30d)
496 filings
490 filers
Visit website
Investor relations